Respiratory viral infections in the elderly: From the perspective of the aging immune system
-
GRAPHICAL ABSTRACT
DownLoad:
Full size image
-
PUBLIC SUMMARY
-
The elderly have a worse prognosis after respiratory viral infections.
Aging immune system with low efficacy leads to ineffective viral clearance.
Individualized assessment of immune status is necessary for appropriate treatment.
Modulating the aging immune system is a crucial treatment strategy.
-
-
ABSTRACT
The susceptibility of the elderly to respiratory viral infections and the challenges posed by an aging population necessitate imperative development of advanced preventive and therapeutic strategies for elderly individuals. The clinical outcome of such infections is intricately determined by the complex interplay among viruses, host tissues, and immune cells. Elderly individuals exhibit a diminished efficacy of their immune system to clear viruses, consequently leading to prolonged viral insults, tissue damage, and an excessive activation of inflammatory cells. These ultimately result in worse clinical outcomes. Targeting the dysregulated antiviral immune responses has emerged as a potential approach to improve the prognosis of geriatric patients. It is noteworthy that the impacts of aging on antiviral immune responses are highly heterogenous. Thus, individualized patient assessment and management assume paramount importance. This review aims to summarize the current evidence elucidating the effects of aging on immune responses to respiratory viruses, with the ultimate goal of identifying knowledge gaps that can inform future research and enhance the management of elderly individuals. -
-
REFERENCES
[1] WHO. (2020). Leading causes of death and disability 2000-2019: A visual summary. https://www.who.int/data/stories/leading-causes-of-death-and-disability-2000-2019-a-visual-summary. [2] Ruuskanen, O., Lahti, E., Jennings, L.C., et al. (2011). Viral pneumonia. Lancet 377: 1264−1275. DOI: 10.1016/S0140-6736(10)61459-6. [3] Jain, S. (2017). Epidemiology of viral pneumonia. Clin. Chest Med. 38: 1−9. DOI: 10.1016/j.ccm.2016.11.012. [4] Jain, S., Self, W.H., Wunderink, R.G., et al. (2015). Community-acquired pneumonia requiring hospitalization among US. adults. N. Engl. J. Med. 373: 415−427. DOI: 10.1056/NEJMoa1500245. [5] Zhou, F., Wang, Y., Liu, Y., et al. (2019). Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: A multicentre prospective registry study from the CAP-China Network. Eur. Respir. J. 54 : 1802406. DOI: 10.1183/13993003.02406-2018. [6] WHO. (2023). WHO coronavirus (COVID-19) dashboard. https://covid19.who.int (accessed on June 23rd, 2023). [7] Hansen, C.L., Chaves, S.S., Demont, C., et al. (2022). Mortality associated with influenza and respiratory syncytial virus in the US, 1999-2018. JAMA Netw. Open 5: e220527. DOI: 10.1001/jamanetworkopen.2022.0527. [8] Cohen, C., Walaza, S., Treurnicht, F.K., et al. (2018). In- and out-of-hospital mortality associated with seasonal and pandemic influenza and respiratory syncytial virus South Africa, 2009-2013. Clin. Infect. Dis. 66: 95−103. DOI: 10.1093/cid/cix740. [9] Matias, G., Taylor, R., Haguinet, F., et al. (2014). Estimates of mortality attributable to influenza and RSV in the United States during 1997-2009 by influenza type or subtype, age, cause of death, and risk status. Influenza Other Respir. Viruses 8: 507−515. DOI: 10.1111/irv.12258. [10] Fleming, D.M., Taylor, R.J., Lustig, R.L., et al. (2015). Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect. Dis. 15: 443. DOI: 10.1186/s12879-015-1218-z. [11] Heppe-Montero, M., Gil-Prieto, R., Del Diego Salas, J., et al. (2022). Impact of respiratory syncytial virus and influenza virus infection in the adult population in Spain between 2012 and 2020. Int. J. Environ. Res. Public Health 19 : 14680. DOI: 10.3390/ijerph192214680. [12] Nazareno, A.L., Muscatello, D.J., Turner, R.M., et al. (2022). Modelled estimates of hospitalisations attributable to respiratory syncytial virus and influenza in Australia, 2009-2017. Influenza Other Respir. Viruses 16: 1082−1090. DOI: 10.1111/irv.13003. [13] Kyeyagalire, R., Tempia, S., Cohen, A.L., et al. (2014). Hospitalizations associated with influenza and respiratory syncytial virus among patients attending a network of private hospitals in South Africa, 2007-2012. BMC Infect. Dis. 14: 694. DOI: 10.1186/s12879-014-0694-x. [14] Qi, L., Li, Q., Ding, X.B., et al. (2020). Mortality burden from seasonal influenza in Chongqing, China, 2012-2018. Hum. Vaccin. Immunother. 16: 1668−1674. DOI: 10.1080/21645515.2019.1693721. [15] Park, M., Wu, P., Goldstein, E., et al. (2016). Influenza-associated excess mortality in South Korea. Am. J. Prev. Med. 50: e111−e119. DOI: 10.1016/j.amepre.2015.09.028. [16] Murray, C.J., Lopez, A.D., Chin, B., et al. (2006). Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: A quantitative analysis. Lancet 368: 2211−2218. DOI: 10.1016/S0140-6736(06)69895-4. [17] Louie, J.K., Jean, C., Acosta, M., et al. (2011). A review of adult mortality due to 2009 pandemic (H1N1) influenza A in California. PLoS One 6: e18221. DOI: 10.1371/journal.pone.0018221. [18] Shaw, E.R., and Su, H.C. (2021). The influence of immune immaturity on outcome after virus infections. J. Allergy Clin. Immunol. Pract. 9: 641−650. DOI: 10.1016/j.jaip.2020.11.016. [19] Centers for Disease Control and Prevention. (2022). Risk for COVID-19 infection, hospitalization, and death by age group. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html (accessed on June 26th, 2023). [20] COVID-19 Forecasting Team. (2022). Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: A systematic analysis. Lancet 399: 1469−1488. DOI: 10.1016/S0140-6736(21)02867-1. [21] Dzau, V.J., Inouye, S.K., Rowe, J.W., et al. (2019). Enabling healthful aging for all - the national academy of medicine grand challenge in healthy longevity. N. Engl. J. Med. 381: 1699−1701. DOI: 10.1056/NEJMp1912298. [22] Berbudi, A., Rahmadika, N., Tjahjadi, A.I., et al. (2020). Type 2 diabetes and its impact on the immune system. Curr. Diabetes Rev. 16: 442−449. DOI: 10.2174/1573399815666191024085838. [23] Syed-Ahmed, M., and Narayanan, M. (2019). Immune dysfunction and risk of infection in chronic kidney disease. Adv. Chronic Kidney Dis. 26: 8−15. DOI: 10.1053/j.ackd.2019.01.004. [24] Bhat, T.A., Panzica, L., Kalathil, S.G., et al. (2015). Immune dysfunction in patients with chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc. 12 Suppl 2 : S169-175. DOI: 10.1513/AnnalsATS.201503-126AW. [25] Kuek, L.E., and Lee, R.J. (2020). First contact: The role of respiratory cilia in host-pathogen interactions in the airways. Am. J. Physiol. Lung Cell Mol. Physiol. 319: L603−l619. DOI: 10.1152/ajplung.00283.2020. [26] Ho, J.C., Chan, K.N., Hu, W.H., et al. (2001). The effect of aging on nasal mucociliary clearance, beat frequency, and ultrastructure of respiratory cilia. Am. J. Respir. Crit. Care Med. 163: 983−988. DOI: 10.1164/ajrccm.163.4.9909121. [27] Proença de Oliveira-Maul, J., Barbosa de Carvalho, H., Goto, D.M., et al. (2013). Aging, diabetes, and hypertension are associated with decreased nasal mucociliary clearance. Chest 143: 1091-1097. DOI: 10.1378/chest.12-1183. [28] Svartengren, M., Falk, R., and Philipson, K. (2005). Long-term clearance from small airways decreases with age. Eur. Respir. J. 26: 609−615. DOI: 10.1183/09031936.05.00002105. [29] Moliva, J.I., Rajaram, M.V., Sidiki, S., et al. (2014). Molecular composition of the alveolar lining fluid in the aging lung. Age (Dordr) 36: 9633. DOI: 10.1007/s11357-014-9633-4. [30] Lehmann, R., Müller, M.M., Klassert, T.E., et al. (2018). Differential regulation of the transcriptomic and secretomic landscape of sensor and effector functions of human airway epithelial cells. Mucosal Immunol. 11: 627−642. DOI: 10.1038/mi.2017.100. [31] Wosen, J.E., Mukhopadhyay, D., Macaubas, C., et al. (2018). Epithelial MHC class II expression and its role in antigen presentation in the gastrointestinal and respiratory tracts. Front. Immunol. 9: 2144. DOI: 10.3389/fimmu.2018.02144. [32] Chason, K.D., Jaspers, I., Parker, J., et al. (2018). Age-associated changes in the respiratory epithelial response to influenza infection. J. Gerontol. A Biol. Sci. Med. Sci. 73: 1643−1650. DOI: 10.1093/gerona/gly126. [33] Chen, J., Deng, J.C., Zemans, R.L., et al. (2022). Age-induced prostaglandin E(2) impairs mitochondrial fitness and increases mortality to influenza infection. Nat. Commun. 13: 6759. DOI: 10.1038/s41467-022-34593-y. [34] Yin, L., Zheng, D., Limmon, G.V., et al. (2014). Aging exacerbates damage and delays repair of alveolar epithelia following influenza viral pneumonia. Respir. Res. 15: 116. DOI: 10.1186/s12931-014-0116-z. [35] Lambrecht, B.N. (2006). Alveolar macrophage in the driver's seat. Immunity 24: 366-368. DOI: 10.1016/j.immuni.2006.03.008. [36] Morales-Nebreda, L., Misharin, A.V., Perlman, H., et al. (2015). The heterogeneity of lung macrophages in the susceptibility to disease. Eur. Respir. Rev. 24: 505−509. DOI: 10.1183/16000617.0031-2015. [37] Mould, K.J., Barthel, L., Mohning, M.P., et al. (2017). Cell origin dictates programming of resident versus recruited macrophages during acute lung injury. Am. J. Respir. Cell Mol. Biol. 57: 294−306. DOI: 10.1165/rcmb.2017-0061OC. [38] Shi, C., and Pamer, E.G. (2011). Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 11: 762−774. DOI: 10.1038/nri3070. [39] Iwasaki, A., Foxman, E.F., and Molony, R.D. (2017). Early local immune defences in the respiratory tract. Nat. Rev. Immunol. 17: 7−20. DOI: 10.1038/nri.2016.117. [40] Metcalf, T.U., Cubas, R.A., Ghneim, K., et al. (2015). Global analyses revealed age-related alterations in innate immune responses after stimulation of pathogen recognition receptors. Aging Cell 14: 421-432. DOI: 10.1111/acel.12320. [41] Metcalf, T.U., Wilkinson, P.A., Cameron, M.J., et al. (2017). Human monocyte subsets are transcriptionally and functionally altered in aging in response to pattern recognition receptor agonists. J. Immunol. 199: 1405−1417. DOI: 10.4049/jimmunol.1700148. [42] Molony, R.D., Nguyen, J.T., Kong, Y., et al. (2017). Aging impairs both primary and secondary RIG-I signaling for interferon induction in human monocytes. Sci. Signal 10 : eaan2392. DOI: 10.1126/scisignal.aan2392. [43] Johansson, C., and Kirsebom, F.C.M. (2021). Neutrophils in respiratory viral infections. Mucosal Immunol. 14: 815−827. DOI: 10.1038/s41385-021-00397-4. [44] Lim, K., Hyun, Y.M., Lambert-Emo, K., et al. (2015). Neutrophil trails guide influenza-specific CD8+ T cells in the airways. Science 349: aaa4352. DOI: 10.1126/science.aaa4352. [45] Kulkarni, U., Zemans, R.L., Smith, C.A., et al. (2019). Excessive neutrophil levels in the lung underlie the age-associated increase in influenza mortality. Mucosal Immunol. 12: 545−554. DOI: 10.1038/s41385-018-0115-3. [46] Wong, C.K., Smith, C.A., Sakamoto, K., et al. (2017). Aging impairs alveolar macrophage phagocytosis and increases influenza-induced mortality in mice. J. Immunol. 199: 1060−1068. DOI: 10.4049/jimmunol.1700397. [47] Fu, B., Tian, Z., and Wei, H. (2014). Subsets of human natural killer cells and their regulatory effects. Immunology 141: 483-489. DOI: 10.1111/imm.12224. [48] Björkström, N.K., Strunz, B., and Ljunggren, H.G. (2022). Natural killer cells in antiviral immunity. Nat. Rev. Immunol. 22: 112−123. DOI: 10.1038/s41577-021-00558-3. [49] Luczo, J.M., Ronzulli, S.L., and Tompkins, S.M. (2021). Influenza A virus hemagglutinin and other pathogen glycoprotein interactions with NK cell natural cytotoxicity receptors NKp46, NKp44, and NKp30. Viruses 13 : 156. DOI: 10.3390/v13020156. [50] Zhou, G., Juang, S.W., and Kane, K.P. (2013). NK cells exacerbate the pathology of influenza virus infection in mice. Eur. J. Immunol. 43: 929−938. DOI: 10.1002/eji.201242620. [51] Nogusa, S., Ritz, B.W., Kassim, S.H., et al. (2008). Characterization of age-related changes in natural killer cells during primary influenza infection in mice. Mech. Ageing Dev. 129: 223−230. DOI: 10.1016/j.mad.2008.01.003. [52] Beli, E., Clinthorne, J.F., Duriancik, D.M., et al. (2011). Natural killer cell function is altered during the primary response of aged mice to influenza infection. Mech. Ageing Dev. 132: 503−510. DOI: 10.1016/j.mad.2011.08.005. [53] Kopf, M., Schneider, C., and Nobs, S.P. (2015). The development and function of lung-resident macrophages and dendritic cells. Nat. Immunol. 16: 36−44. DOI: 10.1038/ni.3052. [54] Jakubzick, C., Helft, J., Kaplan, T.J., et al. (2008). Optimization of methods to study pulmonary dendritic cell migration reveals distinct capacities of DC subsets to acquire soluble versus particulate antigen. J. Immunol. Methods 337: 121−131. DOI: 10.1016/j.jim.2008.07.005. [55] Kim, T.S., and Braciale, T.J. (2009). Respiratory dendritic cell subsets differ in their capacity to support the induction of virus-specific cytotoxic CD8+ T cell responses. PLoS One 4: e4204. DOI: 10.1371/journal.pone.0004204. [56] Lin, K.L., Suzuki, Y., Nakano, H., et al. (2008). CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. J. Immunol. 180: 2562−2572. DOI: 10.4049/jimmunol.180.4.2562. [57] Toapanta, F.R., and Ross, T.M. (2009). Impaired immune responses in the lungs of aged mice following influenza infection. Respir. Res. 10: 112. DOI: 10.1186/1465-9921-10-112. [58] Zhao, J., Zhao, J., Legge, K., et al. (2011). Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. J. Clin. Invest. 121: 4921−4930. DOI: 10.1172/JCI59777. [59] Liu, W.M., Nahar, T.E., Jacobi, R.H., et al. (2012). Impaired production of TNF-α by dendritic cells of older adults leads to a lower CD8+ T cell response against influenza. Vaccine 30: 1659-1666. DOI: 10.1016/j.vaccine.2011.12.105. [60] Langlois, R.A., and Legge, K.L. (2010). Plasmacytoid dendritic cells enhance mortality during lethal influenza infections by eliminating virus-specific CD8 T cells. J. Immunol. 184: 4440−4446. DOI: 10.4049/jimmunol.0902984. [61] Sridharan, A., Esposo, M., Kaushal, K., et al. (2011). Age-associated impaired plasmacytoid dendritic cell functions lead to decreased CD4 and CD8 T cell immunity. Age (Dordr) 33: 363-376. DOI: 10.1007/s11357-010-9191-3. [62] Prakash, S., Agrawal, S., Cao, J.N., et al. (2013). Impaired secretion of interferons by dendritic cells from aged subjects to influenza : Role of histone modifications. Age (Dordr) 35: 1785−1797. DOI: 10.1007/s11357-012-9477-8. [63] Levavi, H., Lancman, G., and Gabrilove, J. (2021). Impact of rituximab on COVID-19 outcomes. Ann. Hematol. 100: 2805−2812. DOI: 10.1007/s00277-021-04662-1. [64] Carr, E.J., Dooley, J., Garcia-Perez, J.E., et al. (2016). The cellular composition of the human immune system is shaped by age and cohabitation. Nat. Immunol. 17: 461−468. DOI: 10.1038/s41590-020-00839-4. [65] Alpert, A., Pickman, Y., Leipold, M., et al. (2019). A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. Nat. Med. 25: 487−495. DOI: 10.1038/s41591-019-0381-y. [66] Yahata, T., Takanashi, T., Muguruma, Y., et al. (2011). Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells. Blood 118: 2941−2950. DOI: 10.1182/blood-2011-01-330050. [67] Pang, W.W., Price, E.A., Sahoo, D., et al. (2011). Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc. Natl. Acad. Sci. U. S. A. 108 : 20012-20017. DOI: 10.1073/pnas.1116110108. [68] Tuljapurkar, S.R., McGuire, T.R., Brusnahan, S.K., et al. (2011). Changes in human bone marrow fat content associated with changes in hematopoietic stem cell numbers and cytokine levels with aging. J. Anat. 219: 574−581. DOI: 10.1111/j.1469-7580.2011.01423.x. [69] Sempowski, G.D., Hale, L.P., Sundy, J.S., et al. (2000). Leukemia inhibitory factor, oncostatin M, IL-6, and stem cell factor mRNA expression in human thymus increases with age and is associated with thymic atrophy. J. Immunol. 164: 2180−2187. DOI: 10.4049/jimmunol.164.4.2180. [70] Britanova, O.V., Putintseva, E.V., Shugay, M., et al. (2014). Age-related decrease in TCR repertoire diversity measured with deep and normalized sequence profiling. J. Immunol. 192: 2689−2698. DOI: 10.4049/jimmunol.1302064. [71] Yoshida, K., Cologne, J.B., Cordova, K., et al. (2017). Aging-related changes in human T-cell repertoire over 20years delineated by deep sequencing of peripheral T-cell receptors. Exp. Gerontol. 96: 29−37. DOI: 10.1016/j.exger.2017.05.015. [72] Qi, Q., Liu, Y., Cheng, Y., et al. (2014). Diversity and clonal selection in the human T-cell repertoire. Proc. Natl. Acad. Sci. U. S. A. 111: 13139−13144. DOI: 10.1073/pnas.1409155111. [73] Gibson, K.L., Wu, Y.C., Barnett, Y., et al. (2009). B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell 8: 18-25. DOI: 10.1111/j.1474-9726.2008.00443.x. [74] de Bourcy, C.F., Angel, C.J., Vollmers, C., et al. (2017). Phylogenetic analysis of the human antibody repertoire reveals quantitative signatures of immune senescence and aging. Proc. Natl. Acad. Sci. U. S. A. 114: 1105−1110. DOI: 10.1073/pnas.1617959114. [75] Yager, E.J., Ahmed, M., Lanzer, K., et al. (2008). Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J. Exp. Med. 205: 711−723. DOI: 10.1084/jem.20071140. [76] Gil, A., Yassai, M.B., Naumov, Y.N., et al. (2015). Narrowing of human influenza A virus-specific T cell receptor α and β repertoires with increasing age. J. Virol. 89: 4102−4116. DOI: 10.1128/JVI.03020-14. [77] Gallerani, E., Proietto, D., Dallan, B., et al. (2021). Impaired priming of SARS-CoV-2-specific naive CD8(+) T cells in older subjects. Front. Immunol. 12: 693054. DOI: 10.3389/fimmu.2021.693054. [78] Zheng, Y., Liu, X., Le, W., et al. (2020). A human circulating immune cell landscape in aging and COVID-19. Protein Cell 11: 740-770. DOI: 10.1007/s13238-020-00762-2. [79] Bahadoran, A., Lee, S.H., Wang, S.M., et al. (2016). Immune responses to influenza virus and its correlation to age and inherited factors. Front. Microbiol. 7: 1841. DOI: 10.3389/fmicb.2016.01841. [80] Rydyznski Moderbacher, C., Ramirez, S.I., Dan, J.M., et al. (2020). Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183: 996-1012.e1019. DOI: 10.1016/j.cell.2020.09.038. [81] Lefebvre, J.S., Masters, A.R., Hopkins, J.W., et al. (2016). Age-related impairment of humoral response to influenza is associated with changes in antigen specific T follicular helper cell responses. Sci. Rep. 6: 25051. DOI: 10.1038/srep25051. [82] Lu, L., Yu, S., Liu, M., et al. (2022). SARS-CoV-2-specific antibody response characteristics in COVID-19 patients of different ages. Acta Biochim. Biophys. Sin. (Shanghai) 54: 556−564. DOI: 10.3724/abbs.2022014. [83] Selva, K.J., van de Sandt, C.E., Lemke, M.M., et al. (2021). Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nat. Commun. 12: 2037. DOI: 10.1038/s41467-021-22236-7. [84] Garcia-Beltran, W.F., Lam, E.C., Astudillo, M.G., et al. (2021). COVID-19-neutralizing antibodies predict disease severity and survival. Cell 184: 476-488.e411. DOI: 10.1016/j.cell.2020.12.015. [85] Po, J.L., Gardner, E.M., Anaraki, F., et al. (2002). Age-associated decrease in virus-specific CD8+ T lymphocytes during primary influenza infection. Mech. Ageing Dev. 123 : 1167-1181. DOI: 10.1016/s0047-6374(02)00010-6. [86] Williams-Bey, Y., Jiang, J., and Murasko, D.M. (2011). Expansion of regulatory T cells in aged mice following influenza infection. Mech. Ageing Dev. 132: 163−170. DOI: 10.1016/j.mad.2011.03.001. [87] Westmeier, J., Paniskaki, K., Karaköse, Z., et al. (2020). Impaired cytotoxic CD8(+) T cell response in elderly COVID-19 patients. mBio 11 : e02243-20. DOI: 10.1128/mBio.02243-20. [88] Goplen, N.P., Wu, Y., Son, Y.M., et al. (2020). Tissue-resident CD8(+) T cells drive age-associated chronic lung sequelae after viral pneumonia. Sci. Immunol. 5 : eabc4557. DOI: 10.1126/sciimmunol.abc4557. [89] Morales-Nebreda, L., Helmin, K.A., Torres Acosta, M.A., et al. (2021). Aging imparts cell-autonomous dysfunction to regulatory T cells during recovery from influenza pneumonia. JCI Insight 6 : e141690. DOI: 10.1172/jci.insight.141690. [90] Humbert, M., Olofsson, A., Wullimann, D., et al. (2023). Functional SARS-CoV-2 cross-reactive CD4(+) T cells established in early childhood decline with age. Proc. Natl. Acad. Sci. U. S. A. 120: e2220320120. DOI: 10.1073/pnas.2220320120. [91] Zhao, M., Chen, J., Tan, S., et al. (2018). Prolonged evolution of virus-specific memory t cell immunity after severe avian influenza A (H7N9) virus infection. J. Virol. 92 : e01024-18. DOI: 10.1128/JVI.01024-18. [92] Ho, F.K., Petermann-Rocha, F., Gray, S.R., et al. (2020). Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants. PLoS One 15 : e0241824. DOI: 10.1371/journal.pone.0241824. [93] Fajnzylber, J., Regan, J., Coxen, K., et al. (2020). SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat. Commun. 11: 5493. DOI: 10.1038/s41467-020-19057-5. [94] Kawasuji, H., Morinaga, Y., Tani, H., et al. (2022). SARS-CoV-2 RNAemia with a higher nasopharyngeal viral load is strongly associated with disease severity and mortality in patients with COVID-19. J. Med. Virol. 94: 147−153. DOI: 10.1002/jmv.27282. [95] Bermejo-Martin, J.F., González-Rivera, M., Almansa, R., et al. (2020). Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. Crit. Care 24: 691. DOI: 10.1186/s13054-020-03398-0. [96] Vasquez, C.R., Gupta, S., Miano, T.A., et al. (2021). Identification of distinct clinical subphenotypes in critically ill patients with COVID-19. Chest 160: 929-943. DOI: 10.1016/j.chest.2021.04.062. [97] López-Martínez, C., Martín-Vicente, P., Gómez de Oña, J., et al. (2023). Transcriptomic clustering of critically ill COVID-19 patients. Eur. Respir. J. 61 : 2200592. DOI: 10.1183/13993003.00592-2022. [98] Nguyen, Q.D., Moodie, E.M., Forget, M.F., et al. (2021). Health heterogeneity in older adults: Exploration in the canadian longitudinal study on aging. J. Am. Geriatr. Soc. 69: 678−687. DOI: 10.1111/jgs.16919. [99] Del Valle, D.M., Kim-Schulze, S., Huang, H.H., et al. (2020). An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26: 1636−1643. DOI: 10.1038/s41591-020-1051-9. [100] McElvaney, O.J., McEvoy, N.L., McElvaney, O.F., et al. (2020). Characterization of the inflammatory response to severe COVID-19 illness. Am. J. Respir. Crit. Care Med. 202: 812−821. DOI: 10.1164/rccm.202005-1583OC. [101] Mogilenko, D.A., Shchukina, I., and Artyomov, M.N. (2022). Immune ageing at single-cell resolution. Nat. Rev. Immunol. 22: 484−498. DOI: 10.1038/s41577-021-00646-4. [102] Keenan, C.R., and Allan, R.S. (2019). Epigenomic drivers of immune dysfunction in aging. Aging Cell 18: e12878. DOI: 10.1111/acel.12878. [103] Reis, G., Moreira Silva, E.A.S., Medeiros Silva, D.C., et al. (2023). Early treatment with pegylated interferon lambda for COVID-19. N. Engl. J. Med. 388: 518−528. DOI: 10.1056/NEJMoa2209760. [104] Pan, H., Peto, R., Henao-Restrepo, A.M., et al. (2021). Repurposed antiviral drugs for COVID-19 - interim WHO Solidarity trial results. N. Engl. J. Med. 384: 497−511. DOI: 10.1056/NEJMoa2023184. [105] Shankar-Hari, M., Vale, C.L., Godolphin, P.J., et al. (2021). Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA 326: 499−518. DOI: 10.1001/jama.2021.11330. [106] Zhang, X., Shang, L., Fan, G., et al. (2021). The efficacy and safety of Janus kinase inhibitors for patients with COVID-19: A living systematic review and meta-analysis. Front. Med. (Lausanne) 8: 800492. DOI: 10.3389/fmed.2021.800492. [107] Netea, M.G., Joosten, L.A., Latz, E., et al. (2016). Trained immunity: A program of innate immune memory in health and disease. Science 352: aaf1098. DOI: 10.1126/science.aaf1098. [108] Netea, M.G., Domínguez-Andrés, J., Barreiro, L.B., et al. (2020). Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 20: 375−388. DOI: 10.1038/s41577-020-0285-6. [109] Bekkering, S., Domínguez-Andrés, J., Joosten, L.A.B., et al. (2021). Trained immunity: Reprogramming innate immunity in health and disease. Annu. Rev. Immunol. 39: 667−693. DOI: 10.1146/annurev-immunol-102119-073855. [110] Giamarellos-Bourboulis, E.J., Tsilika, M., Moorlag, S., et al. (2020). Activate: Randomized clinical trial of BCG vaccination against infection in the elderly. Cell 183: 315−323.e319. DOI: 10.1016/j.cell.2020.08.051. [111] Tsilika, M., Taks, E., Dolianitis, K., et al. (2022). ACTIVATE-2: A double-blind randomized trial of BCG vaccination against COVID-19 in individuals at risk. Front. Immunol. 13: 873067. DOI: 10.3389/fimmu.2022.873067. [112] Debisarun, P.A., Gössling, K.L., Bulut, O., et al. (2021). Induction of trained immunity by influenza vaccination - impact on COVID-19. PLoS Pathog 17: e1009928. DOI: 10.1371/journal.ppat.1009928. [113] Pittet, L.F., Messina, N.L., Orsini, F., et al. (2023). Randomized trial of BCG vaccine to protect against COVID-19 in health care workers. N. Engl. J. Med. 388: 1582−1596. DOI: 10.1056/NEJMoa2212616. [114] Weinberger, B., Herndler-Brandstetter, D., Schwanninger, A., et al. (2008). Biology of immune responses to vaccines in elderly persons. Clin. Infect. Dis. 46: 1078−1084. DOI: 10.1086/529197. [115] Schwarz, T., Tober-Lau, P., Hillus, D., et al. (2021). Delayed antibody and T-cell response to BNT162b2 vaccination in the elderly, Germany. Emerg. Infect. Dis. 27: 2174−2178. DOI: 10.3201/eid2708.211145. [116] Wei, J., Stoesser, N., Matthews, P.C., et al. (2021). Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat. Microbiol. 6: 1140−1149. DOI: 10.1038/s41564-021-00947-3. [117] Meng, Z., Zhang, J., Shi, J., et al. (2020). Immunogenicity of influenza vaccine in elderly people: A systematic review and meta-analysis of randomized controlled trials, and its association with real-world effectiveness. Hum. Vaccin. Immunother. 16: 2680−2689. DOI: 10.1080/21645515.2020.1747375. [118] Collier, D.A., Ferreira, I., Kotagiri, P., et al. (2021). Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 596: 417-422. DOI: 10.1038/s41586-021-03739-1. [119] Gilbert, P.B., Montefiori, D.C., McDermott, A.B., et al. (2022). Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375: 43-50. DOI: 10.1126/science.abm3425. [120] Khoury, D.S., Cromer, D., Reynaldi, A., et al. (2021). Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27: 1205−1211. DOI: 10.1038/s41591-021-01377-8. [121] Bell, M.R., and Kutzler, M.A. (2022). An old problem with new solutions: Strategies to improve vaccine efficacy in the elderly. Adv. Drug Deliv. Rev. 183: 114175. DOI: 10.1016/j.addr.2022.114175. [122] Wilkinson, K., Wei, Y., Szwajcer, A., et al. (2017). Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. Vaccine 35: 2775-2780. DOI: 10.1016/j.vaccine.2017.03.092. [123] Coleman, B.L., Sanderson, R., Haag, M.D.M., et al. (2021). Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis. Influenza Other Respir. Viruses 15: 813−823. DOI: 10.1111/irv.12871. [124] McElhaney, J.E., Beran, J., Devaster, J.M., et al. (2013). AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: A phase 3 randomised trial. Lancet Infect. Dis. 13: 485−496. DOI: 10.1016/S1473-3099(13)70046-X. [125] Pereira, B., Xu, X.N., and Akbar, A.N. (2020). Targeting inflammation and immunosenescence to improve vaccine responses in the elderly. Front. Immunol. 11: 583019. DOI: 10.3389/fimmu.2020.583019. [126] López-Otín, C., Blasco, M.A., Partridge, L., et al. (2013). The hallmarks of aging. Cell 153: 1194-1217. DOI: 10.1016/j.cell.2013.05.039. [127] Cao, X., Li, W., Wang, T., et al. (2022). Accelerated biological aging in COVID-19 patients. Nat. Commun. 13: 2135. DOI: 10.1038/s41467-022-29801-8. [128] Di Micco, R., Krizhanovsky, V., Baker, D., et al. (2021). Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat. Rev. Mol. Cell Biol. 22: 75−95. DOI: 10.1038/s41580-020-00314-w. [129] Debacq-Chainiaux, F., Erusalimsky, J.D., Campisi, J., et al. (2009). Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat. Protoc. 4: 1798−1806. DOI: 10.1038/nprot.2009.191. [130] Herranz, N., and Gil, J. (2018). Mechanisms and functions of cellular senescence. J. Clin. Invest. 128: 1238−1246. DOI: 10.1172/JCI95148. [131] Hao, X., Wang, C., and Zhang, R. (2022). Chromatin basis of the senescence-associated secretory phenotype. Trends Cell Biol. 32: 513−526. DOI: 10.1016/j.tcb.2021.12.003. [132] Schafer, M.J., Zhang, X., Kumar, A., et al. (2020). The senescence-associated secretome as an indicator of age and medical risk. JCI Insight 5 : e133668. DOI: 10.1172/jci.insight.133668. [133] Kirkland, J.L., and Tchkonia, T. (2020). Senolytic drugs: From discovery to translation. J. Intern. Med. 288: 518−536. DOI: 10.1111/joim.13141. [134] Niedernhofer, L.J., and Robbins, P.D. (2018). Senotherapeutics for healthy ageing. Nat. Rev. Drug Discov. 17: 377. DOI: 10.1038/nrd.2018.44. [135] Gasek, N.S., Kuchel, G.A., Kirkland, J.L., et al. (2021). Strategies for targeting senescent cells in human disease. Nat. Aging 1: 870−879. DOI: 10.1038/s43587-021-00121-8. [136] Kelley, W.J., Zemans, R.L., and Goldstein, D.R. (2020). Cellular senescence: Friend or foe to respiratory viral infections? Eur. Respir. J. 56 : 2002708. DOI: 10.1183/13993003.02708-2020. [137] Camell, C.D., Yousefzadeh, M.J., Zhu, Y., et al. (2021). Senolytics reduce coronavirus-related mortality in old mice. Science 373 : eabe4832. DOI: 10.1126/science.abe4832. [138] Evangelou, K., Veroutis, D., Paschalaki, K., et al. (2022). Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: Possible implications for viral mutagenesis. Eur. Respir. J. 60 : 2102951. DOI: 10.1183/13993003.02951-2021. [139] Lee, S., Yu, Y., Trimpert, J., et al. (2021). Virus-induced senescence is a driver and therapeutic target in COVID-19. Nature 599: 283-289. DOI: 10.1038/s41586-021-03995-1. [140] Di Pierro, F., Derosa, G., Maffioli, P., et al. (2021). Possible therapeutic effects of adjuvant quercetin supplementation against early-stage COVID-19 infection: A prospective, randomized, controlled, and open-label study. Int. J. Gen. Med. 14: 2359−2366. DOI: 10.2147/IJGM.S318720. [141] Di Pierro, F., Iqtadar, S., Khan, A., et al. (2021). Potential clinical benefits of quercetin in the early stage of COVID-19: Results of a second, pilot, randomized, controlled and open-label clinical trial. Int. J. Gen. Med. 14: 2807−2816. DOI: 10.2147/IJGM.S318949. [142] Johnson, S.C., Rabinovitch, P.S., and Kaeberlein, M. (2013). mTOR is a key modulator of ageing and age-related disease. Nature 493: 338-345. DOI: 10.1038/nature11861. [143] Powell, J.D., Pollizzi, K.N., Heikamp, E.B., et al. (2012). Regulation of immune responses by mTOR. Annu. Rev. Immunol. 30: 39−68. DOI: 10.1146/annurev-immunol-020711-075024. [144] Quinn, K.M., Palchaudhuri, R., Palmer, C.S., et al. (2019). The clock is ticking: the impact of ageing on T cell metabolism. Clin. Transl. Immunol. 8: e01091. DOI: 10.1002/cti2.1091. [145] Mannick, J.B., Del Giudice, G., Lattanzi, M., et al. (2014). mTOR inhibition improves immune function in the elderly. Sci. Transl. Med. 6: 268ra179. DOI: 10.1126/scitranslmed.3009892. [146] Mannick, J.B., Morris, M., Hockey, H.P., et al. (2018). TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci. Transl. Med. 10 : eaaq1564. DOI: 10.1126/scitranslmed.aaq1564. [147] Mannick, J.B., Teo, G., Bernardo, P., et al. (2021). Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: Phase 2b and phase 3 randomised trials. Lancet Healthy Longev. 2: e250−e262. DOI: 10.1016/S2666-7568(21)00062-3. [148] Cao, S., Zhang, Q., Song, L., et al. (2022). Dysregulation of innate and adaptive immune responses in asymptomatic SARS-CoV-2 infection with delayed viral clearance. Int. J. Biol. Sci. 18: 4648−4657. DOI: 10.7150/ijbs.72963. [149] Bjornson-Hooper, Z.B., Fragiadakis, G.K., Spitzer, M.H., et al. (2022). A comprehensive atlas of immunological differences between humans, mice, and non-human primates. Front. Immunol. 13: 867015. DOI: 10.3389/fimmu.2022.867015. [150] Lu, J., Duan, X., Zhao, W., et al. (2018). Aged mice are more resistant to influenza virus infection due to reduced inflammation and lung pathology. Aging Dis. 9: 358−373. DOI: 10.14336/AD.2017.0701. [151] Sun, S., Zhao, G., Xiao, W., et al. (2011). Age-related sensitivity and pathological differences in infections by 2009 pandemic influenza A (H1N1) virus. Virol. J. 8: 52. DOI: 10.1186/1743-422X-8-52. [152] Smith, C.A., Kulkarni, U., Chen, J., et al. (2019). Influenza virus inoculum volume is critical to elucidate age-dependent mortality in mice. Aging Cell 18: e12893. DOI: 10.1111/acel.12893. [153] Califano, D., Furuya, Y., and Metzger, D.W. (2018). Effects of influenza on alveolar macrophage viability are dependent on mouse genetic strain. J. Immunol. 201: 134−144. DOI: 10.4049/jimmunol.1701406. [154] Wang, J., Li, F., Sun, R., et al. (2013). Bacterial colonization dampens influenza-mediated acute lung injury via induction of M2 alveolar macrophages. Nat. Commun. 4: 2106. DOI: 10.1038/ncomms3106. [155] Salahudeen, A.A., Choi, S.S., Rustagi, A., et al. (2020). Progenitor identification and SARS-CoV-2 infection in human distal lung organoids. Nature 588: 670-675. DOI: 10.1038/s41586-020-3014-1. [156] Francis, I., Shrestha, J., Paudel, K.R., et al. (2022). Recent advances in lung-on-a-chip models. Drug Discov. Today 27: 2593-−2602. DOI: 10.1016/j.drudis.2022.06.004. [157] McClain, M.T., Constantine, F.J., Nicholson, B.P., et al. (2021). A blood-based host gene expression assay for early detection of respiratory viral infection: an index-cluster prospective cohort study. Lancet Infect Dis 21: 396-404. DOI: 10.1016/S1473-3099(20)30486-2. [158] Lydon, E.C., Henao, R., Burke, T.W., et al. (2019). Validation of a host response test to distinguish bacterial and viral respiratory infection. EBioMedicine 48: 453-461. DOI: 10.1016/j.ebiom.2019.09.040. -
ABOUT THIS ARTICLE
Cite this article:
Zhang X., Xu J., Wang Y., et al., (2023). Respiratory viral infections in the elderly: From the perspective of the aging immune system. The Innovation Medicine 1(2), 100022. https://doi.org/10.59717/j.xinn-med.2023.100022
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
Zhang X., Xu J., Wang Y., et al., (2023). Respiratory viral infections in the elderly: From the perspective of the aging immune system. The Innovation Medicine 1(2), 100022. https://doi.org/10.59717/j.xinn-med.2023.100022
Format
Content
-
Figure 1.
Immune responses triggered by respiratory viral infections
-
Figure 2.
The interactions among viruses, host tissues, and immune responses in young adults and the elderly
